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CD26/dipeptidyl peptidase IV (DPPIV) is a cell surface-bound ectopeptidase with important roles in T-cell activation and tumour
biology. We now report that CD26/DPPIV enhances sensitivity to apoptosis induced by the antineoplastic agents doxorubicin and
etoposide. In particular, CD26/DPPIV presence is associated with increased susceptibility to the mitochondrial pathway of apoptosis,
documented by enhanced cleavage of poly (ADP ribose) polymerase (PARP), caspase-3 and caspase-9, Bcl-xl, and Apaf-1, as well as
increased expression of death receptor 5 (DR5). We also show that the caspase-9-specific inhibitor z-LEHD-fmk inhibits drug-
mediated apoptosis, leading to decreased PARP and caspase-3 cleavage, and reduced DR5 expression. Importantly, through detailed
studies that demonstrate the association between topoisomerase II alpha expression and DPPIV activity, our data provide further
evidence of the key role played by CD26 in biological processes.
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CD26 is a 110-kDa type II cell surface glycoprotein with diverse
functional properties that is widely expressed on various tissues
(Dang and Morimoto, 2002; Sato and Dang, 2003). Its extracellular
domain encodes a membrane-associated dipeptidyl peptidase IV
(DPPIV) activity capable of processing amino-terminal dipeptides
from polypeptides with either L-proline or L-alanine in the
penultimate position (Oravecz et al, 1997). In addition, CD26 acts
as an alternative pathway of T-cell activation through its physical
and functional association with molecules involved in T-cell signal
transduction processes, including CD45, mannose 6-phosphate/
insulin-like growth factor II receptor and adenosine deaminase
(ADA) (Morimoto et al, 1989; Dang et al, 1990a–d, 1991; Ishii et al,
2001; Dang and Morimoto, 2002; Sato and Dang, 2003). With its
deficiency being a cause of severe combined immune deficiency,
ADA plays a key role in the development and function of lymphoid
tissues and by regulating surface expression of ADA, CD26
potentially has an important role in adenosine metabolism and
immune regulation (Sato and Dang, 2003). Meanwhile, recent
findings suggest that CD26 has a role in the development of certain
types of neoplasms (Morrison et al, 1993; Sedo and Revoltella,
1995; Tanaka et al, 1995; Stecca et al, 1997). B-chronic lymphocytic
leukaemia cells have high levels of CD26 protein expression and
mRNA transcripts (Bauvois et al, 1999); whereas the more
aggressive T-cell malignancies, such as T-cell acute lymphoblastic
leukaemia or T-cell CD30þ anaplastic large-cell lymphoma,
express higher CD26 level as compared to the more indolent T-
cell diseases like mycosis fungoides (Carbone et al, 1995; Jones
et al, 2001).
Topoisomerase II inhibitors are widely used agents in cancer
treatment (Froelich-Ammon and Osheroff, 1995), exploiting the
catalytic activity of topoisomerase II alpha by increasing permanent
DNA damage (Beck et al, 1999). Previous findings have shown that
DNA damage mediated by topoisomerase II inhibitors induces
apoptosis (Beck et al, 1999; Mow et al, 2001), particularly through
cytochrome c release (Liu et al, 1996; Kluck et al, 1997), Apaf-1
involvement (Perkins et al, 2000; Lauber et al, 2001), and
subsequent caspase-9 activation (Mow et al, 2001). We have
previously shown that surface expression of CD26/DPPIV enhances
sensitivity of CD26 Jurkat T-cell transfectants to G2/M arrest
mediated by the topoisomerase II inhibitors doxorubicin and
etoposide (Aytac et al, 2001, 2003). Expanding on these previous
findings, we now examine the effect of CD26/DPPIV expression on
apoptosis induced by doxorubicin and etoposide. In this paper, we
demonstrate that CD26/DPPIV presence enhances sensitivity to
apoptosis induced by topoisomerase II inhibitors, associated with
increased cleavage of Bcl-xl, Apaf-1, procaspase-9, procaspase-3,
and PARP, as well as increased expression of DR5. Meanwhile,
pretreatment with the caspase-9-specific inhibitor z-LEHD-fmk
significantly reduces etoposide-mediated apoptotic events. Impor-
tantly, we present detailed data from different experimental
approaches demonstrating the association between DPPIV enzyme
activity and topoisomerase II alpha expression. Our findings thus
emphasise the increasingly important role of the multifaceted Received 28 March 2003; revised 15 July 2003; accepted 15 July 2003
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sCD26/DPPIV molecule in biological processes, while the functional
association between CD26/DPPIV and topoisomerase II alpha may
be exploited for future treatments of selected cancers.
MATERIALS AND METHODS
Cells and reagents
Human CD26 Jurkat T-cell leukaemia stable transfectants have
been described and characterised previously regarding CD26
surface expression and associated DPPIV enzyme activity (Aytac
et al, 2001, 2003). The Jurkat cell lines include: (a) wild-type CD26-
transfected Jurkat cell lines (wtCD26); (b) Jurkat cell lines
transfected with mutant CD26 containing an alanine at the putative
catalytic serine residue at position 630, resulting in a mutant CD26-
positive/DPPIV-negative Jurkat transfectant (S630A); (c) Jurkat cell
lines transfected with mutant CD26 containing point mutations at
ADA-binding site residues 340–343, with amino acid L340, V341,
A342, and R343 being replaced by amino acids P340, S341, E342,
and Q343, resulting in a mutant CD26-positive/DPPIV-positive
Jurkat transfectant incapable of binding ADA (340–344); and (d)
nontransfected control Jurkat cells (parental). Jurkat transfectants
were maintained in culture media, which consisted of RPMI 1640
supplemented with 10% FCS, penicillin (100Uml
 1), streptomycin
(100mgml
 1), and G418 (0.25mgml
 1; Life Technologies Inc., NY,
USA) Nontransfectant control Jurkat cells were maintained in the
same culture media without G418. Annexin V- fluorescein
isothiocyanate (FITC) was from BD PharMingen, CA, USA.
Anti-PARP, cytochrome c, and caspase-3 Abs were from BD Phar-
Mingen; anti-actin was from Sigma Chemical Co, MO, USA;
anti-caspase-9wasfrom Cayman, MI, USA.Anti-DR5 Abswerefrom
Cayman. Anti-Bcl-xl and Apaf-1 Abs were from BD Transduction
Laboratories, CA, USA. Anti-topoisomerase II alpha was from
Roche, IN, USA. Caspase-9 inhibitor (z-LEHD-fmk) was from BD
PharMingen. Diisopropyl fluorophosphate (DFP) was obtained
from SIGMA, MO, USA. Substrate for DPPIV, Gly-Pro-p-nitroa-
nilide-tosylate (GPNT), was purchased from WAKO, Japan.
Etoposide was purchased from SIGMA and was dissolved in sterile
DMSO. Doxorubicin was purchased from Calbiochem, CA, USA
and was dissolved in sterile PBS. Soluble CD26molecules were
produced by Chinese hamster ovary cells and purified as described
previously (Tanaka et al, 1994).
Annexin/propidium iodide (PI) assays
Exposure of phosphatidylserine residues was quantified by surface
Annexin V staining as previously described (Raynal and Pollard,
1994). Briefly, cells were washed in binding buffer (10mM HEPES,
pH 7.4, 2.5mM CaCl2, 140mM NaCl), resuspended in 100ml and
incubated with 0.5mlml
 1 annexin V-FITC and 2.5mgml
 1 PI for
15min in the dark. Cells were then washed again and resuspended
in 400ml of binding buffer, then flow cytometric analysis
(FACScan; Becton Dickinson, CA, USA) was performed. A total
of 10000 cells were acquired per sample and data were analysed
using Cellquest software (Becton Dickinson).
SDS–PAGE and immunoblotting
After incubation at 371C in culture media and etoposide or
doxorubicin at the concentrations and duration indicated, cells
were harvested from wells, washed with PBS, and lysed in lysis
buffer consisting of 1% NP-40, 0.5%, deoxycolate, 0.1% SDS, 1mM
phenylmethylsulphonyl fluoride, 1mM benzamidine, 10mgml
 1
aprotinin, 50mgml
 1 leupeptin, 10mgml
 1 soybean trypsin
inhibitor and 1mgml
 1 pepstatin. After incubating on ice for
5min, nuclei were removed by centrifugation and supernatants
were collected as whole-cell lysates. Sample buffer (4 ) consisting
of 20% glycerol, 4.6% SDS, 0.5 M Tris (pH 6.8), 4% b-
mercaptoethanol, and 0.2% bromophenol blue was added to the
appropriate aliquots of supernatants. After boiling, protein
samples were submitted to SDS–PAGE analysis on an 8% gel
under standard conditions using a mini-Protean II system (Bio-
Rad, CA, USA). For immunoblotting, the proteins were transferred
onto nitrocellulose (Immobilon-P; Millipore, MA, USA). After
overnight blocking at 41C in blocking solution consisting of 0.1%
Tween 20 and 5% BSA in Tris-buffered saline, membranes were
blotted with the appropriate primary antibodies diluted in
blocking solution for 1h at room temperature. Membranes were
then washed with blocking solution, and appropriate secondary
antibodies diluted in blocking solution were then applied for 1h at
room temperature. Secondary antibodies were goat anti-mouse or
goat anti-rabbit horseradish peroxidase conjugates (Dako).
Membranes were then washed with blocking solution, and proteins
were subsequently detected by chemiluminescence (Amersham
Pharmacia Biotech, NJ, USA).
Dipeptidyl Peptidase IV enzyme activity assays
As previously described (Kajiyama et al, 2002), DPPIV enzyme
activity was measured spectrophotometrically using GPNT, a
substrate for DPPIV. A 1  PBS-washed whole-cell suspension was
prepared and 5 10
5 cells were resuspended in 200ml of PBS into
96-well plate, then GPNT was added at a final concentration of
0.24mM. The absorption was measured at 405nm using microplate
spectrophotometer (BIO-TEK Instruments, inc., VE, USA) twice,
just before the addition of the substrate and after 60min
incubation at 371C. Dipeplidyl peptidase enzyme activity was
calculated from the increase of absorption between 0 and 60min.
Inhibition of DPPIV enzyme activity
As described previously (Koreeda et al, 2001; Kajiyama et al, 2002),
DFP was used as the DPPIV chemical inhibitor for inhibition
assays. To evaluate effect of continuous exposure to DFP, wtCD26
transfectants or parental Jurkat cells were incubated in culture
media alone (DFP ), culture media containing 100mM DFP for 2h
or for 6h (DFPþ). A representative sample of cells reflecting each
treatment condition was obtained for DPPIV enzyme activity
assays or to examine topoisomerase II alpha expression. Alter-
natively, wtCD26 Jurkat transfectants were incubated in culture
media; or in culture media with 100mM DFP for 4h; or they were
incubated in culture media with 100mM DFP for 4h, then washed
twice in PBS to ensure removal of DFP followed by incubation in
culture media for 2 or 8h. A representative sample of cells
reflecting each treatment condition was obtained for DPPIV
enzyme activity assays or to examine topoisomerase II alpha
expression. For all treatment conditions, trypan blue uptake assays
consistently showed 490% cell viability (data not shown).
Preparation of cytosol fractions
As previously described (Haridas et al, 2001; Nishimura et al,
2001), Jurkat cells (4.0 10
7) were suspended in 1ml sucrose
buffer (250mM sucrose in 30mM Tris HCl, pH 7.4) and transferred
into an N2 cavitation chamber (PARR Instruments, Moline, IL,
USA). The cells were subjected to N2 cavitation (250psi for 5min)
according to the manufacturer’s instructions. Under these condi-
tions, most of the cell membrane was disrupted with no change in
the mitochondrial respiratory activity. Next, DNA and the nuclear
fraction were removed by centrifugation (1500g for 2min). The
supernatant was further centrifuged (16000g for 10min), and the
supernatant was used as the cytosol fraction.
Preparation of nuclear extracts
Cells (10 10
6) were harvested and allowed to swell for 15min on
ice in cytoplasmic extraction buffer (10mM HEPES, 10mM KCl,
CD26 and sensitivity to topoisomerase II inhibitors
K Sato et al
1367
British Journal of Cancer (2003) 89(7), 1366–1374 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s0.1mM EDTA, 0.1mM EGTA, 1mM DTT, 1mM PMSF, 2mgml
 1
leupeptin, 2mgml
 1aprotinin, and 0.5mgml
 1 benzamidine).
Then NP-40 (final concentration 0.3%) was added into that cell
suspension and vortexed for 10s. After 2min-centrifugation at
16000g, the supernatant was discarded. The pellet was then
incubated with nuclear extraction buffer (20mM HEPES, 400mM
KCl, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.5mM PMSF, 2mgml
 1
leupeptin, 2mgml
 1 aprotinin, and 0.5mgml
 1 benzamidine) for
30min on ice with intermittent vortexing. The suspension was
centrifuged at 16000g for 6min, and the supernatant was saved as
the nuclear extract.
RESULTS
Effect of CD26/DPPIV expression on apoptosis of Jurkat
cells mediated by topoisomerase II inhibitors
Annexin V/PI assays show that wtCD26 Jurkat transfectants are
more sensitive to the apoptotic effect of etoposide than S630A or
parental control Jurkat cells. Meanwhile, 340–4 transfectants
(340–4) exhibit higher level of drug-induced apoptosis, similar to
that of wtCD26 transfectants (Figure 1A). Furthermore, wtCD26
and 340–4 cells display greater apoptosis when treated with
doxorubicin as compared with parental or S630A Jurkat cells
(Figure 1B). Time course studies to evaluate the effect of
doxorubicin on apoptosis in these CD26 Jurkat transfectants are
also performed. Our data show that wtCD26 Jurkat transfectants
consistently exhibit greater drug-induced apoptosis over the time
intervals and drug concentrations tested than parental Jurkat
(Figure 1C), strongly suggesting that the presence of CD26 directly
enhances cellular sensitivity to topoisomerase II inhibitor-induced
apoptosis. Similar results are obtained with etoposide treatment
(data not shown). Similarly, both the wtCD26 and 340–4 Jurkat
transfectants are more sensitive to etoposide-mediated PARP
cleavage (Figure 2), as compared with parental cells and S630A
transfectants. Similar results are seen when cells are treated with
doxorubicin. These data hence suggest that the presence of CD26,
especially its associated DPPIV enzymatic activity, enhances
apoptosis mediated by topoisomerase II inhibitors.
Effect of CD26/DPPIV surface expression on the
mitochondrial pathway of apoptosis induced by etoposide
Previous work demonstrated that DNA damage mediated by
topoisomerase II inhibitors induces apoptosis through the
mitochondrial pathway. Our time course analyses (Figure 3) show
that etoposide treatment results in enhanced cleavage of PARP and
procaspase-3, leading to increased levels of the cleaved 17kDa
caspase-3 bands in wtCD26 transfectants, as compared with S630A
and parental Jurkat cells. Moreover, our work shows that etoposide
treatment leads to significantly greater cleavage of procaspase-9 in
wtCD26 cells compared to S630A and parental control Jurkat. We
also demonstrate greater cleavage of the 130kDa proform of Apaf-
1 in etoposide-treated wtCD26 Jurkat transfectants as compared
with parental control or S630A Jurkat. Furthermore, the increase in
sensitivity to etoposide-induced apoptosis in wtCD26 transfectants
is accompanied by greater cleavage of the full-length antiapoptotic
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Figure 1 Enhancing effect of CD26/DPPIV surface expression on
apoptosis induced by topoisomerase II inhibitors. CD26 Jurkat transfectants
were incubated at 371C in culture media alone or culture media containing
etoposide (A) for 14h or doxorubicin (B) for 16h at the concentrations
indicated. Cells were then harvested and Annexin V/PI assays were
performed as described in Materials and Methods. wtCD26: wild-type
CD26 Jurkat transfectant; S630A: Jurkat cells transfected with mutant CD26
containing an alanine at the putative catalytic serine residue at position 630,
resulting in a mutant CD26-positive/DPPIV-negative Jurkat transfectant;
control: nontransfected parental Jurkat; 340–4: Jurkat cells transfected with
mutant CD26 containing point mutations at the ADA-binding site residues
340–343, with amino acids L340,V 341,A 342, and R343 being replaced by
amino acids P340,S 341,E 342, and Q343, resulting in a mutant CD26-positive/
DPPIV-positive mutant CD26 Jurkat transfectant incapable of binding ADA.
Data are representative of three separate experiments. (C) wtCD26 Jurkat
transfectants and parental cells were treated with doxorubicin over the
indicated time intervals and drug concentrations. a: 12h, b: 24h, c: 36h.
Data are representative of three separate experiments.
c
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smolecule Bcl-xl (Fujita et al, 1998) and a resultant rise in the
18kDa cleaved band. Taken together, our results indicate that
CD26/DPPIV enhances etoposide-mediated apoptosis of Jurkat
cells by affecting cellular processes known to be involved in drug-
mediated apoptosis, including those involving caspase-9 proces-
sing and the mitochondrial pathway, as well as processing of bcl-2-
related molecules. Similarly, time course analyses demonstrate that
wtCD26 Jurkat transfectants exhibit greater apoptosis through
caspase-9 processing when treated with doxorubicin, as demon-
strated by greater cleavage of PARP and procaspase-9.
Effect of the caspase-9 inhibitor z-LEHD-fmk on etoposide-
induced apoptosis in CD26 Jurkat transfectants
To further confirm our findings that CD26 affects etoposide-
induced apoptosis through caspase-9-related events, we evaluated
the effect of the caspase-9 inhibitor z-LEHD-fmk on this process.
Western blot analyses show that pretreatment with z-LEHD-fmk
significantly abrogates the effect of etoposide on wtCD26 Jurkat
transfectants. As shown in Figure 4, etoposide-mediated cleavage
of procaspase-9 is inhibited by z-LEHD-fmk in a dose-dependent
manner. Furthermore, cleavage of procaspase-3 and PARP, events
downstream of caspase-9 processing, is significantly reduced
following pretreatment with the caspase-9 inhibitor. Our data
therefore indicate CD26 augments etoposide-induced apoptosis in
CD26 Jurkat transfectants through caspase-9-related events.
Similarly, pretreatment with z-LEHD-fmk significantly decreases
the effect of doxorubicin on wtCD26 Jurkat transfectants, as
measured by cleavage of PARP and procaspase-9.
Effect of the DPPIV enzyme inhibitor DFP on
topoisomerase II alpha expression
We previously showed that topoisomerase II alpha expression and
catalytic activity are higher in wtCD26 Jurkat transfectant than
S630A or parental cells (Aytac et al, 2003) (Figure 5A). To further
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
104
103
102
101
100
100 101 102 103 104
F
L
2
-
H
F
L
2
-
H
F
L
2
-
H
F
L
2
-
H
F
L
2
-
H
F
L
2
-
H
FL1-H FL1-H FL1-H FL1-H
FL1-H FL1-H FL1-H FL1-H
FL1-H FL1-H FL1-H FL1-H
C
o
n
t
r
o
l
w
t
C
D
2
6
C
o
n
t
r
o
l
w
t
C
D
2
6
C
o
n
t
r
o
l
w
t
C
D
2
6
0 0.1 0.5 1 doxo (M)
C
a
b
c
Figure 1 Continued.
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sevaluate in detail the effect of DPPIV activity on topoisomerase II
alpha expression, we examined the effect of the DPPIV chemical
inhibitor DFP (Koreeda et al, 2001; Kajiyama et al, 2002) on
topoisomerase II alpha expression. Continuous treatment with
DFP results in inhibition of DPPIV enzyme activity in wtCD26
Jurkat transfectants (Figure 5B), associated with decreased
expression of topoisomerase II alpha in these cells (Figure 5C).
On the other hand, expression of topoisomerase II alpha in
parental Jurkat cells is not significantly affected by continuous
exposure to DFP, as expected. Additionally, we examined the
status of DPPIV enzyme activity and topoisomerase II alpha
expression following DFP treatment. For this purpose, following
treatment with DFP, wtCD26 cells were washed and incubated in
culture media for the indicated time periods. We demonstrate that
recovery of DPPIV enzyme activity is associated with recovery of
topoisomerase II expression (Figure 5D and E). These results
further corroborate and expand on our earlier findings regarding
the importance of DPPIV enzyme activity in topoisomerase II
alpha expression in CD26 Jurkat transfectants.
Effect of soluble CD26molecules on topoisomerase II alpha
expression and sensitivity to doxorubicin
It is theoretically possible that DPPIV effect is dependent on
surface expression of the intact CD26/DPPIV molecule. To address
this issue, we evaluate the effect of soluble CD26 (sCD26)
molecules on topoisomerase II alpha expression. As shown in
Figure 6, incubation with sCD26molecules results in a significant
increase in topoisomerase II alpha protein expression in parental
control Jurkat cells (A) or Jiyoye cells (B). Along with an increase
in topoisomerase II alpha expression, incubation of parental Jurkat
cells with sCD26molecules also results in enhanced doroxubicin-
induced or etoposide-induced PARP cleavage (Figure 7). Our
findings further confirm that the presence of DPPIV activity itself,
and not necessarily surface expression of CD26/DPPIV, augments
0 1 301 3 0 1 301 3
wtCD26 340−4 S630A Control
eto (M)
doxo (M)
PARP
PARP
wtCD26 S630A Control
0 0.5 1 0 0.5 1 0 0.5 1
Figure 2 CD26/DPPIV-associated enhancement in PARP cleavage
induced by topoisomerase II inhibitors. CD26 Jurkat transfectants were
incubated at 371C with media containing etoposide for 16h or doxorubicin
for 18h at the indicated doses. Cells were then harvested, and whole-cell
lysates were obtained. Following SDS–PAGE of lysates, immunoblotting
studies for PARP and b-actin were performed as described in Materials and
Methods. The cleaved product of PARP was detected at B85kDa. Each
lane was loaded with 30mg of protein.
wtCD26 S630A Control eto 3 M
time (h)
time (h)
0 6 12 24 48 0 6 12 24 48 0 6 12 24 48
wtCD26 S630A Control
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doxo 1M
PARP
PARP
Caspase 9
-Actin
Caspase 9
Caspase 3
-Actin
*
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**
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Figure 3 Time course study of the effect of CD26/DPPIV surface
expression on etoposide-induced apoptosis. Jurkat cells were incubated at
371C with media containing 3mM etoposide or 1mM doxorubicin for the
indicated time periods at the indicated doses. Cells were then harvested,
and cytosol fractions were obtained as described in Materials and Methods.
Following SDS–PAGE of lysates, immunoblotting studies with specific
antibodies for PARP, caspase-9, caspase-3, Apaf-1, Bcl-xl, and b-actin were
performed as described in Materials and methods (*): caspase-3 cleaved
products; (**): Bcl-xl cleaved products. Each lane was loaded with 30mgo f
protein.
00 2 0 50 75 100
033 3 3 3
0 0 50 75 100
0 1 1 11 doxo (M)
z-LEHD-fmk (M)
PARP
Caspase 9
Caspase 9
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Figure 4 Effect of caspase-9 inhibitor z-LEHD-fmk on etoposide-
induced apoptosis in wtCD26 Jurkat transfectant. wtCD26 Jurkat
transfectants were incubated at 371C for 2h of preincubation with z-
LEHD-fmk at varying doses, and then treated with 3mM etoposide or 1mM
doxorubicin for 16h. Cells were then harvested, and whole-cell lysates
were obtained as described in Materials and Methods. Following SDS–
PAGE of lysates, immunoblotting studies for PARP, caspase-3, caspase-9,
and b-actin were performed as described in Materials and Methods (*):
caspase-3 cleaved products. Each lane was loaded with 30mg of protein.
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stopoisomerase II alpha expression, leading to a resultant increase
in sensitivity to topoisomerase II inhibitors.
Caspase-9-dependent involvement of DR5 in etoposide-
induced apoptosis in CD26 Jurkat transfectants
Expression of death receptor 5 (DR5), a member of the TRAIL
(tumour necrosis factor-related apoptosis-inducing ligand) family,
is upregulated following treatment with such DNA-damaging
agents as doxorubicin and etoposide (Gibson et al, 2000). We now
demonstrate that etoposide treatment leads to a greater increase in
the levels of the 58kDa DR5 in wtCD26 transfectants as compared
with S630A or parental Jurkat cells (Figure 8A). Interestingly,
Western blotting analyses with anti-DR5mAb also detect the
expression of a smaller 32kDa band with etoposide treatment, with
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Figure 5 Effect of inhibition of DPPIV activity on topoisomerase II alpha
expression. (A) After incubation of Jurkat cells at 371C for 24h in culture
media, cells were harvested and nuclear extracts were obtained. Following
SDS–PAGE of lysates, immunoblotting studies were performed for
topoisomerase II alpha or b-actin as described in Materials and Methods.
Each lane was loaded with 30mg of protein. Lane 1: wtCD26 Jurkat
transfectant, lane 2: S630A mutant transfectant, lane 3: parental Jurkat. (B)
wtCD26 Jurkat transfectants or parental Jurkat were incubated in culture
media alone (DFP ), culture media containing 100mM DFP for 2 or 6h
(DFPþ). A representative sample of cells reflecting each treatment
condition was obtained, and DPPIV enzyme activity assays were then
performed as described in Materials and Methods. (C) wtCD26 Jurkat
transfectants (lanes 1–3) or parental Jurkat (lanes 4–6) were incubated in
culture media alone (lanes 1, 3), culture media containing 100mM DFP for
2h (lanes 2, 5) or for 6h (lanes 3, 6). Cells were harvested, and nuclear
− + sCD26
topo II alpha
-Actin
− + sCD26
topo II alpha
-Actin
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Figure 6 Effect of soluble CD26molecules on topoisomerase II alpha
expression. Parental Jurkat cells (A) or Jiyoye cells (B) were incubated
overnight in culture media alone ( ) or culture media containing soluble
CD26 (sCD26) molecules (300mgml
 1)( þ)a t3 7 1C. Cells were then
harvested and nuclear extracts were obtained. Following SDS–PAGE of
lysates, immunoblotting studies for topoisomerase II alpha or b-actin were
performed as described in Materials and Methods. Each lane was loaded
with 30mg of protein.
extracts were obtained. Following SDS–PAGE of lysates, immunoblotting
studies for topoisomerase II alpha or b-actin were performed as described
in Materials and Methods. Each lane was loaded with 30mg of protein. (D)
wtCD26 Jurkat transfectants were incubated in culture media (bar I), or in
culture media with 100mM DFP for 4h (bar II), or they were incubated in
culture media with 100mM DFP for 4h, then washed twice in PBS to ensure
removal of DFP followed by incubation in culture media for 2h (bar III) or
8h (bar IV). A representative sample of cells reflecting each treatment
condition was obtained, and DPPIV enzyme activity assays were then
performed as described in Materials and Methods. (E) wtCD26 Jurkat
transfectants were incubated in culture media (lane 1), or in culture media
with 100mM DFP for 4h (lane 2), or they were incubated in culture media
with 100mM DFP for 4h, then washed twice in PBS to ensure removal of
DFP followed by incubation in culture media for 2h (lane 3) or 8h (lane 4).
Cells were then harvested and nuclear extracts were obtained. Following
SDS–PAGE of lysates, immunoblotting studies for topoisomerase II alpha
or b-actin were performed as described in Materials and Methods. Each
lane was loaded with 30mg of protein.
b— ———————————————————————————————
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S630A or parental cells. In time course studies, the appearance of
the 32kDa band consistently precedes the observed increase in
expression levels of the 58kDa band.
We have already demonstrated that etoposide-induced apopto-
sis in wtCD26 Jurkat transfectant involves caspase-9 processing.
To determine whether the enhancement in DR5 expression in
etoposide-treated wtCD26 Jurkat is dependent on caspase-9-
related events, we examined DR5 expression in cells treated with
etoposide following preincubation with the caspase-9-specific
inhibitor z-LEHD-fmk. As demonstrated in Figure 8B, the increase
in the 58kDa band seen in etoposide-treated wtCD26 cells is
significantly attenuated when cells are preincubated with z-LEHD-
fmk. In addition, the 32kDa band induced by etoposide is no
longer detectable with z-LEHD-fmk preincubation. Concordant
with the findings with etoposide, pretreatment with z-LEHD-fmk
similarly inhibits doxorubicin effect on DR5 status.
DISCUSSION
Through experiments involving CD26 Jurkat transfectants, DPPIV
chemical inhibitor and soluble CD26/DPPIV molecules, we provide
conclusive evidence that presence of DPPIV enzyme activity
results in enhanced topoisomerase II alpha expression, associated
with increased sensitivity to apoptosis induced by topoisomerase
II inhibitors. Topoisomerase II enzyme plays an important role in
the metabolism of DNA topoisomers and is essential for cellular
proliferation (Wang, 1996). Two topoisomerase II isoforms, alpha
and beta, exist in eukaryotes, coded by two different genes (Drake
et al, 1989; Goswami et al, 1996). In particular, the 170kDa
topoisomerase II alpha isoform is closely associated with the cell
cycle, being highly expressed during cellular proliferation, and is
the primary target of such topoisomerase II inhibitors as
doxorubicin or etoposide (Burden and Osheroff, 1998). These
drugs selectively exploit the catalytic activity of topoisomerase II
alpha to create DNA damage by increasing the frequency and
duration of DNA cleavage sites, causing permanent double-
stranded breaks and leading to apoptosis (Froelich-Ammon and
Osheroff, 1995; Beck et al, 1999; Mow et al, 2001). Owing to this
mechanism of toxicity, increased enzyme level is associated with
enhanced sensitivity, and drug resistance is related with reduced
topoisomerase II alpha level (Beck et al, 1993, Oloumi et al, 2000).
Our current findings that the enhanced topoisomerase II alpha
expression associated with CD26/DPPIV presence results in greater
− −−+ ++
− −− + ++
0 5 10 0 5 10
0 33 0 3 30 0 doxo (M)
sCD26
PARP
sCD26
PARP
eto (M)
Figure 7 CD26-associated enhancement of doxorubicin or etoposide-
induced PARP cleavage. Parental Jurkat cells were incubated overnight in
culture media alone ( ) or culture media containing soluble CD26
(sCD26) molecules (300mgml
 1)( þ)a t3 7 1C, followed by incubation
with doxorubicin or etoposide at the indicated concentrations for 16h.
Cells were then harvested, and whole-cell lysates were obtained as
described in Materials and Methods. Following SDS–PAGE of lysates,
immunoblotting studies for PARP or b-actin were performed as described
in Materials and Methods. Each lane was loaded with 30mg of protein.
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Figure 8 Effect of CD26/DPPIV on DR5 expression induced by etoposide treatment. (A) Jurkat cells were incubated at 371C in culture media containing
etoposide (3mM) for the indicated time periods at the indicated doses. Cells were then harvested, and whole-cell lysates were obtained as described in
Materials and Methods. Following SDS–PAGE of lysates, immunoblotting studies for DR5 and b-actin were performed as described in Materials and
Methods. Each lane was loaded with 30mg of protein. Anti- DR5mAb detects two bands of 58 and 32kDa. (B) Following 2h of preincubation at 371C with
varying doses of z-LEHD-fmk, wtCD26 Jurkat transfectants were treated with 3mM etoposide or 1mM doxorubicin for 48h. Cells were then harvested, and
whole cell lysates were obtained as described in Materials and Methods. Following SDS–PAGE of lysates, immunoblotting studies for DR5, caspase-9, and b-
actin were performed as described in Materials and Methods. Each lane was loaded with 30mg of protein.
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therefore consistent with the known mechanism of action of these
topoisomerase II inhibitors.
Etoposide or doxorubicin engages the caspase-9-related mito-
chondrial pathway of apoptosis (Sun et al, 1999). It is also known
that perturbation of Bcl-2-related proteins such as Bcl-xl is
important for apoptotic processes associated with drug-induced
DNA damage, potentially augmenting death signals from the
mitochondrial pathway (Liu et al, 1996; Kluck et al, 1997; Fujita
et al, 1998). Our results, including those demonstrating increased
drug-induced Bcl-xl cleavage associated with CD26/DPPIV expres-
sion and the effect of the caspase-9-specific inhibitor z-LEHD-fmk,
are consistent with the conclusion that the CD26/DPPIV-associated
increase in apoptosis induced by the topoisomerase II inhibitors is
mediated through caspase-9 processing and the mitochondrial
pathway. Nevertheless, it is theoretically possible that CD26 exerts its
influence on cell growth inhibition via other additional pathway(s).
Our results also indicate that CD26/DPPIV expression is
associated with enhancement of not only the 58kDa DR5 protein,
but also the smaller 32kDa form following topoisomerase II
inhibitor treatment of Jurkat cells. While being consistent with
previous reports demonstrating that DR5 expression is upregu-
lated following treatment with DNA-damaging agents (Gibson et al,
2000), our work also demonstrates the existence of the smaller
32kDa band. While the exact relationship between the 32kDa band
and the full-length 58kDa band remains to be elucidated, one
potential explanation from our work would be that the smaller band
represents a precursor form of DR5. Our time course experiments
show that while the 32kDa band is not detected in untreated cells,
its appearance in cells treated with etoposide precedes the detectable
increase in the expression levels of the 58kDa band. Additionally,
the pretreatment with the caspase-9 inhibitor z-LEHD-fmk com-
pletely inhibits topoisomerase II inhibitor-induced expression of the
32kDa band while abrogating the increased expression of the 58kDa
band. Besides our demonstration of the existence of the 32kDa
band, our work also reveals a functional relationship between
caspase-9 and DR5. Previous work has indicated that death signals
related with DR5 are subsequently transmitted downstream to
caspase-9 processing events (Gibson et al,2 0 0 0 ) .H o w e v e r ,o u r
findings suggest that caspase-9 processing also affects DR5
expression following drug-induced DNA damage, since pretreat-
ment with the caspase-9 inhibitor z-LEHD-fmk negatively affects
expression levels of both the 58 and 32kDa bands in topoisomerase
II inhibitor-treated cells.
Previously published work suggested that CD26/DPPIV expres-
sion renders human T cells more responsive to activation signals
from various stimuli (Dang and Morimoto, 2002). In addition,
CD26 expression on selected human tumours are associated with
aggressive tumour behaviour (Carbone et al, 1995; Sato and Dang,
2003). Our present findings of the association between CD26/
DPPIV and topoisomerase II alpha expression may potentially
provide an explanation for these previous observations. In view of
the role played by topoisomerase II alpha in cellular proliferation,
it is possible that the biological behaviour of these CD26-bearing
cells reflects in part the higher levels of topoisomerase II alpha.
Our present work thus provides additional evidence of the
essential role of the multifaceted CD26molecule in cellular
processes. Furthermore, along with our recent study indicating
an antitumour effect of anti-CD26mAb (Ho et al, 2001), our
findings may provide insights into the design of future novel
treatments against selected human tumours based on our knowl-
edge of CD26 biology.
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